The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | The MAIA study and other myeloma highlights from ASH 2018
Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, discusses the Phase III MAIA study (NCT02252172) that’s underway to further establish the role of daratumumab in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM). Prof. Morgan also shares his view on the highlights for myeloma from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
